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LETTERS TO THE EDITOR 
Mediastinal lymph node metastasis in patients 
with clinical stage I lung cancer 
To the Editor." 
I read the recent article by Takizawa and associates 1 
regarding mediastinal lymph node metastasis n patients 
with clinical stage I peripheral non-small-cell lung cancer 
(NSCLC) with great interest. This important study in 575 
patients nicely demonstrates that even in clinical stage I
NSCLC, 14% of patients have N2 disease, moving them 
into stage IIIA. In 68% of these N2 cases, the surgeon 
could not detect the lymph node metastases by macro- 
scopic examination, a fact that stresses the importance of 
complete nodal sampling. 
However, it is surprising that in the discussion the 
authors do not address the role of mediastinoscopy in 
preoperative staging of lung cancer. When looking care- 
fully at Tables III to VII, I observed a total of 79 patients 
with N2 disease; in 61 patients (77.2%) these N2 nodes 
were accessible by cervical mediastinoscopy and in 16 
patients (20.3%) by left anterior mediastinoscopy. If rou- 
tine cervical mediastinoscopy had been performed for 
right-sided tumors, and combined with an anterior or 
extended mediastinoscopy for left-sided tumors, 77 of 79 
or 97.5% of these N2 metastases would have been de- 
tected before the operation. The accuracy of mediastinos- 
copy has been shown to be 95% for superior mediastinal 
involvement. 2 Another advantage of mediastinoscopy is 
contralateral sampling of lymph nodes, which detects 
possible N3 disease. Inasmuch as contralateral node sam- 
pling is difficult by way of a lateral thoracotomy, some 
patients in the study by Takizawa's group, especially those 
with multilevel N2 disease, could have had N3 and thus 
stage IIIB disease. 
Recently, the role of mediastinoscopy has become more 
important because surgery is no longer advocated as 
primary treatment for NSCLC with histologically proved 
N2 involvement. Because overall survival in these patients 
is very poor, many of them are treated by induction 
chemotherapy,3.4 It would be interesting to know the 
overall survival data of the 79 patients with N2 disease in 
the study by Takizawa's group, ~ in which none of the 
patients had preoperative mediastinoscopy and all were 
treated by primary surgery. In my opinion, mediastinos- 
copy should be performed routinely for correct staging of 
NSCLC, because the accuracy of present-day computed 
tomographic s anners in mediastinal staging remains low. 5 
Primary consideration should be given to induction che- 
motherapy in patients with N2 involvement, avoiding 
primary surgical treatment. 
Paul E. Y. Van Schil, MD 
Department of Surgery 
Division of Thoracic and Vascular Surgery 
University Hospital of Antwerp 
Wilrijkstraat 10 
B-2650 Edegem, Belgium 
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Reply to the Editor: 
We appreciate Dr. Van Schil's investigation of the 
data with regard to our patients with N2 disease. His 
investigation shows us that 97.5% of the N2 metastases 
of our patients would have been detected in the preop- 
erative period if cervical or anterior mediastinoscopy 
had been performed. We realize that Dr. Van Schil 
recommends performing mediastinoscopy to detect N2 
disease before thoracotomies. We do not agree with his 
recommendation. We did not perform mediastinoscopy 
in our patients with clinical stage I lung cancer because 
the negative predictive accuracy for mediastinal lymph 
node metastasis with the use of computed tomography 
is high. ~'a Each patient in our article had clinical stage I
lung cancer, which was assessed through computed 
tomography. No patients had enlarged mediastinal 
lymph nodes suggestive of N2 disease. We would have 
had to perform mediastinoscopy on all patients with 
clinical stage I lung cancer to detect N2 disease among 
them. If we had done so, 496 of 575 patients (86%) 
would have been subjected to a needless invasive 
operation. Therefore we think that the practicality of 
performing mediastinoscopy on all patients with clinical 
stage I lung cancer merits further debate. 
Dr. Van Schil asked about the overall survival data of 
the 79 patients with N2 disease in our study. We followed 
up all of our 79 patients with N2 disease. Their overall 
survival, calculated by means of the Kaplan-Meier 
method, was estimated to be 26% at 5 years. Each death 
decreased the proportion surviving in our calculations, 
regardless of the cause of death. Although we believe that 
our surgical treatment for patients with N2 disease is 
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justified, we need to implement induction chemotherapy 
to improve the survival of patients with N2 disease. 
We agree with Dr. Van Schil's opinion: "Primary con- 
sideration should be given to induction chemotherapy in 
patients with N2 involvement, avoiding primary surgical 
treatment." The problem is how to detect N2 disease in 
patients with clinical stage I lung cancer before thoracot- 
omies. We have recently performed video-assisted thora- 
coscopic sampling of mediastinal lymph nodes just before 
thoracotomy in patients with clinical stage I lung cancer. 
We detected N2 disease in some patients and treated 
them with induction chemotherapy. We are preparing to 
publish our methods and results of this study. 
Tsuneyo Takizawa, MD 
Masanori Terashima, MD 
Department of Thoracic Surgery 
Niigata Cancer Center Hospital 
Niigata, Japan 
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Concentration of glutaraldehyde in fixation of 
bioprosthetic valves 
To the Editor: 
We read with great interest the article by Duncan, 
Boughner, and Vesely, 1 in which they concluded that 
better stabilization of the porcine aortic valve can be 
achieved if the tissue is fixed dynamically in glutaralde- 
hyde solution. Dynamic fixation stabilizes the tissue within 
3 hours 15 minutes and 24 hours when the porcine aortic 
valves are cross-linked in 0.5% and 0.05% glutaraldehyde, 
respectively, at room temperature. 1 Schoen, Tsao, and 
Levy 2 have noted that complete glutaraldehyde uptake by 
bioprosthetic tissue occurs within 24 hours of incubation. 
However, it was observed that complete glutaraldehyde 
uptake by bioprosthetic tissue did not occur even in 1 
month after the onset of treatment when the tissue was 
preserved in glutaraldehyde solution of a particular con- 
centration) When a tissue is exposed to glutaraldehyde 
solution of a particular concentration for a certain period, 
it becomes resistant to further penetration of glutaralde- 
hyde molecules from the solution of a particular concen- 
tration. At this stage a slight increase in the concentration 
of glutaraldehyde in the preservative solution is enough 
for further access of glutaraldehyde molecules to the 
interstitium of the tissue, which may be documented by 
measuring the concentration of glutaraldehyde of the 
preservative solution before and after treatment. How- 
ever, a sharp increase in concentration of glutaraldehyde 
in the preservative solution may falsely indicate the corn- 
pletion of saturation of the tissue with glutaraldehyde 
after two or three changes owing to rapid interaction with 
the outer surface of the tissue, and this event may impair 
the further penetration of glutaraldehyde molecules) We 
found that complete stabilization can be attained by 
preserving the tissue in glutaraldehyde solution with grad- 
ual increases in concentrations from 0.1% to 0.25% at 4 ° 
to 10 ° C for more than 8 weeks. During cross-linking of 
the tissue in glutaraldehyde, wechecked the concentration 
of glutaraldehyde in the preservative solution every sev- 
enth day and compared it with that of fresh solution 
spectrophotometrically fter reacting with e-aminocap- 
roic acid. Because the concentration of glutaraldehyde 
was found to decrease in the preservative solution after 
the onset of preservation, the concentration of glutar- 
aldehyde in the preservative solution was increased 
gradually up to 0.25% over a period of more than 8 
weeks, until the concentration was the same as that of 
the fresh solution)'  4However, this period was less than 
4 weeks when the cross-linking was carried out at 
37 ° C. 5 According to our procedure, the cross-linking 
process of a tissue itself dictates the required concen- 
tration of glutaraldehyde and duration of the process at 
a particular temperature. 
The authors j presume that, with their technique, 
there is a possibility of limitation of calcification of 
glutaraldehyde-treated bioprosthetic valves (see Con- 
clusion). Dynamic fixation of bioprosthetic valves in 
glutaraldehyde may promote a better cross-linking pro- 
cess; however, our previous experience 3'4' 6 suggests 
that, short-term or prolonged, adequate or inadequate 
fixation would never change the pathologic feature of 
calcification of bioprostheses when only glutaraldehyde 
treatment is concerned. 
Jyotirmay Chanda, MD 
Ryosei Kuribayashi, MD 
Tadaaki Abe, MD 
Department of Cardiovascular Surgery 
Akita University School of Medicine 
Akita 010, Japan 
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